DaVita Inc. (NYSE:DVA) Receives $161.80 Consensus PT from Analysts

Shares of DaVita Inc. (NYSE:DVA) have been given an average recommendation of “Hold” by the five analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $161.80.

Several brokerages have issued reports on DVA. Truist Financial boosted their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. Barclays upped their target price on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st.

Institutional Investors Weigh In On DaVita

Several institutional investors and hedge funds have recently made changes to their positions in DVA. Transcendent Capital Group LLC acquired a new stake in shares of DaVita during the 3rd quarter worth about $25,000. Blue Trust Inc. grew its stake in DaVita by 56.4% during the third quarter. Blue Trust Inc. now owns 330 shares of the company’s stock worth $54,000 after buying an additional 119 shares during the last quarter. Quarry LP acquired a new stake in shares of DaVita during the third quarter worth approximately $60,000. Point72 Hong Kong Ltd acquired a new position in shares of DaVita in the 2nd quarter worth approximately $68,000. Finally, Versant Capital Management Inc boosted its holdings in shares of DaVita by 58.7% in the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after acquiring an additional 169 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Up 0.9 %

DVA stock opened at $166.28 on Wednesday. DaVita has a twelve month low of $103.40 and a twelve month high of $169.51. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The company has a market cap of $13.63 billion, a PE ratio of 17.94, a price-to-earnings-growth ratio of 0.75 and a beta of 0.92. The business’s 50-day simple moving average is $157.11 and its 200 day simple moving average is $152.71.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. DaVita’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.85 EPS. On average, research analysts anticipate that DaVita will post 9.71 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.